---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-179108"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2024-07-15T23:59:59+00:00"
generated_at: "2026-05-31T20:47:35.036020+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Benitec reports durable swallowing improvements at 180 days for first BB-301 subject in Phase 1b/2a

## Summary
- Post-dose Total Pharyngeal Residue meaningfully reduced at 180 days vs pre-dose average for Subject 1.
- For 3 of 4 food types, TPR at 180 days lower than any point in 9-month natural history study; fourth similar to lowest.
- SSQ Total Score at 180 days lower than any point in 9-month pre-dose period, indicating improved swallowing.
- No SAEs observed; transient Grade 2 GERD previously reported.
- Second subject dosed Feb 2024; third expected Q3 2024; additional interim data in Q1 2025.

## SEC filing metadata
- accession: 0001193125-24-179108
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2024-07-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312524179108/0001193125-24-179108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312524179108/d819205d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-179108
- JSON: https://secwatch.observer/filing/0001193125-24-179108.json
- Plain text: https://secwatch.observer/filing/0001193125-24-179108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.